![]() |
市场调查报告书
商品编码
1963818
自动化分析仪器市场-全球产业规模、份额、趋势、机会、预测:依分析仪器、应用、地区和竞争对手划分,2021-2031年Automated Analyzers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Analyzer, By Application, By Region & Competition, 2021-2031F |
||||||
全球自动化分析仪器市场预计将从 2025 年的 85.9 亿美元成长到 2031 年的 122.1 亿美元,复合年增长率为 6.04%。
这些高通量仪器旨在处理生物检体并进行诊断测试,最大限度地减少人为干预,并采用包括光度法、免疫检测和层析法在内的多种技术。市场成长的主要驱动力是全球慢性病发病率的上升和人口老化。这两方面都要求增加诊断测试的数量,而熟练的实验室技术人员长期短缺则推动了实验室自动化,以提高营运效率并实现快速结果报告。
| 市场概览 | |
|---|---|
| 预测期 | 2027-2031 |
| 市场规模:2025年 | 85.9亿美元 |
| 市场规模:2031年 | 122.1亿美元 |
| 复合年增长率:2026-2031年 | 6.04% |
| 成长最快的细分市场 | 基于免疫疗法的分析仪 |
| 最大的市场 | 北美洲 |
然而,市场扩张的一大障碍是实施这些复杂系统所需的大量资本投入。这对资源有限的小规模检测实验室而言构成了一道财务壁垒。严格的监管标准往往会加剧这种经济压力,并延长产品核可时间。为了说明该行业的规模,MedTech Europe 预测,到 2024 年,欧洲医疗技术市场规模约为 1700 亿欧元,这一数字凸显了该行业巨大的经济规模,而诊断自动化在该行业中发挥着至关重要的作用。
慢性病和感染疾病的蔓延是全球自动化分析仪市场的主要驱动力,从根本上增加了对诊断测试的需求量。随着心血管疾病和癌症等疾病的日益普遍,检查室面临更快处理样本的压力,因此采用高通量自动化分析仪至关重要。世界卫生组织(世卫组织)于2024年5月发布的《2024年世界卫生统计》报告显示,非传染性疾病将占全球死亡人数的74%,凸显了建立健全诊断基础设施的必要性。罗氏公司于2024年2月发布的2023财年年度报告也反映了这一巨大的需求,报告指出,该公司在2023年提供了约290亿次诊断测试。
同时,熟练的实验室专业持续短缺,因此必须引入自动化技术来弥合检测能力与可用劳动力之间的差距。检查室正依靠自动化系统来处理重复性工作,从而减轻人员空缺的影响,并防止员工过度劳累。在人才库日益萎缩的情况下,这对于维持实验室运作至关重要。根据美国临床病理学会于2024年1月发布的《2022年人才短缺调查》数据,实验室技术人员的离职率比疫情前的预测翻了一番,加剧了人才短缺危机。因此,在不增加员工的情况下,自动化对于维持效率至关重要。
引进自动化分析仪器需要大量的资金投入,这构成了市场进入和扩张的主要障碍,尤其对于中小检查室而言更是如此。这些系统在购买、安装和人员培训方面都需要大量的预付费用,这可能会对资源有限的医疗机构造成沉重的预算负担。因此,许多潜在买家被迫推迟采购,继续使用过时的设备。这减缓了先进自动化技术的普及,直接阻碍了整体市场成长,并有效地分割了市场,最终只有资金雄厚的大型机构才能获得先进的高通量解决方案。
这些经济限制因素的影响因医疗服务提供者产业普遍存在的财务不稳定而进一步加剧,限制了其对设备的投资能力。根据美国医院协会 (AHA) 2024 年的报告,医院和医疗系统拥有现金储备的天数与 2022 年相比下降了 28.3%。这场流动性危机限制了其将资金分配给昂贵的资本设备(例如自动化分析仪器)的能力,直接阻碍了新销售,并阻碍了全球市场的扩张。
人工智慧 (AI) 和机器学习在工作流程优化方面的融合,正透过将预测功能直接整合到诊断平台中,从根本上改变全球自动化分析仪市场。检查室越来越多地使用 AI 驱动的演算法来提高结果准确性、实现检体检验自动化并促进预测性维护,从而显着减少非计划仪器停机时间。这项技术进步使医疗机构能够最大限度地利用数据,并从简单的处理转向智慧化的工作流程管理,从而确保持续稳定的运作。为了反映这项创新,MedTech Dive 在 2024 年 10 月报道称,美国 FDA 在 2023 年核准了221 款搭载 AI 或机器学习技术的医疗设备,凸显了这些智慧系统的快速商业化进程。
同时,在产业向分散式检查转型的推动下,小型化、携带式照护现场自动化分析仪正经历决定性的变革。医疗机构正在采用紧凑型多重检测平台,这些平台能够在急诊和院外环境中快速提供与中心检查室同等品质的检测结果,从而减少对中心检查室物流的依赖。这一趋势旨在透过先进的分子诊断和免疫检测技术,加速以患者为中心的临床决策,这些技术经过小型化处理,可在以患者为中心的环境中应用。市场对此技术的强劲需求在生物梅里埃公司于2024年3月发布的《2023财年财务业绩报告》中得到了充分体现。报告显示,光是2023年第四季度,公司就部署了约400台新型BIOFIRE SPOTFIRE照护现场设备,这有力地支持了这些小型化技术的广泛应用。
The Global Automated Analyzers Market is projected to expand from USD 8.59 Billion in 2025 to USD 12.21 Billion by 2031, registering a CAGR of 6.04%. These high-throughput instruments are engineered to process biological samples and execute diagnostic assays with limited human involvement, employing diverse technologies such as photometry, immunoassays, and chromatography. The market's growth is primarily underpinned by the rising global incidence of chronic diseases and an aging demographic, both of which necessitate increased volumes of diagnostic testing, alongside a persistent shortage of skilled laboratory personnel that drives facilities toward automation to ensure operational efficiency and rapid result turnaround times.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 8.59 Billion |
| Market Size 2031 | USD 12.21 Billion |
| CAGR 2026-2031 | 6.04% |
| Fastest Growing Segment | Immuno-based Analyzers |
| Largest Market | North America |
However, a major obstacle hindering widespread market growth is the significant capital investment needed to deploy these complex systems, which creates a financial barrier for smaller laboratories with limited resources. This economic pressure is frequently compounded by strict regulatory standards that extend the timelines for product approval. To demonstrate the sector's magnitude, MedTech Europe estimated the European medical technology market at roughly €170 billion in 2024, a figure that underscores the substantial economic scale of the industry in which diagnostic automation plays a critical role.
Market Driver
The escalating prevalence of chronic and infectious diseases serves as a primary catalyst for the Global Automated Analyzers Market, fundamentally driving up the volume of required diagnostic tests. As conditions such as cardiovascular disorders and cancer become more widespread, laboratories are under pressure to process samples with greater speed, necessitating the adoption of high-throughput automated analyzers. According to the World Health Organization's 'World Health Statistics 2024' report released in May 2024, noncommunicable diseases remained responsible for 74% of all global deaths, highlighting the need for strong diagnostic infrastructure; illustrating the massive operational scale of this demand, Roche's 'Annual Report 2023' from February 2024 noted that the company delivered approximately 29 billion diagnostic tests worldwide in 2023.
Simultaneously, the ongoing shortage of skilled laboratory professionals compels the integration of automation to bridge the gap between testing capacity and the available workforce. Laboratories depend on automated systems to handle repetitive tasks, thereby mitigating the impact of vacancies and preventing staff burnout, a shift that is vital for sustaining operations amid a shrinking talent pool. Data from the American Society for Clinical Pathology's '2022 Vacancy Survey,' published in January 2024, reveals that retirement rates for laboratory professionals have doubled compared to pre-pandemic projections, exacerbating the workforce crisis and making automation a strategic necessity for maintaining efficiency without increasing headcount.
Market Challenge
The substantial capital investment required for automated analyzers represents a formidable barrier to market entry and expansion, particularly for small to medium-sized laboratories. These systems entail significant upfront costs for acquisition, installation, and personnel training, which can severely strain the budgets of resource-limited healthcare facilities. As a result, many potential buyers are compelled to postpone procurement or continue utilizing legacy equipment, which slows the adoption rate of advanced automation technologies and directly impedes overall market growth, effectively segmenting the market by restricting advanced high-throughput solutions to large, well-funded institutions.
The impact of this economic constraint is further intensified by the prevailing financial instability within the healthcare provider sector, which limits capabilities for capital expenditure. According to the American Hospital Association in 2024, hospitals and health systems reported a 28.3% decline in days cash on hand compared to levels observed in 2022. This liquidity crunch restricts the ability of these facilities to allocate funds for expensive capital equipment like automated analyzers, creating a direct impediment to new sales and hampering the broader expansion of the global market.
Market Trends
The Integration of Artificial Intelligence and Machine Learning for Workflow Optimization is fundamentally reshaping the Global Automated Analyzers Market by embedding predictive capabilities directly into diagnostic platforms. Laboratories are increasingly utilizing AI-driven algorithms to improve result accuracy, automate sample validation, and facilitate predictive maintenance, thereby significantly reducing unplanned instrument downtime. This technological evolution enables facilities to maximize data utility, transitioning from simple processing to intelligent workflow management that ensures consistent operational resilience; reflecting this innovation, MedTech Dive reported in October 2024 that the U.S. FDA authorized 221 AI or machine learning-enabled medical devices in 2023, highlighting the rapid commercialization of these intelligent systems.
Concurrently, there is a decisive Shift Towards Miniaturized and Portable Point-of-Care Automated Analyzers, driven by the industry's move toward decentralized testing. Healthcare providers are adopting compact, multiplex platforms that deliver central-lab-quality results rapidly in emergency departments and non-hospital settings, thereby reducing logistical reliance on core laboratories. This trend focuses on accelerating clinical decision-making through advanced molecular and immunoassay technologies scaled down for near-patient use; the market's strong reception is evident in bioMerieux's '2023 Financial Results' from March 2024, which reported the installation of nearly 400 new BIOFIRE SPOTFIRE point-of-care instruments in the fourth quarter of 2023 alone, underscoring the growing uptake of these miniaturized technologies.
Report Scope
In this report, the Global Automated Analyzers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Automated Analyzers Market.
Global Automated Analyzers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: